BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 23852799)

  • 1. Mutation frequency in 15 common cancer genes in high-risk head and neck squamous cell carcinoma.
    McBride SM; Rothenberg SM; Faquin WC; Chan AW; Clark JR; Ellisen LW; Wirth LJ
    Head Neck; 2014 Aug; 36(8):1181-8. PubMed ID: 23852799
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Copy number amplification of the PIK3CA gene is associated with poor prognosis in non-lymph node metastatic head and neck squamous cell carcinoma.
    Suda T; Hama T; Kondo S; Yuza Y; Yoshikawa M; Urashima M; Kato T; Moriyama H
    BMC Cancer; 2012 Sep; 12():416. PubMed ID: 22994622
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Novel mutations of PIK3CA gene in head and neck squamous cell carcinoma.
    Al-Amri AM; Vatte C; Cyrus C; Chathoth S; Hashim TM; Mohamed YS; Al Ali R; Alsaid A; Al Ali A
    Cancer Biomark; 2016; 16(3):377-83. PubMed ID: 26889984
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Distinct pattern of TP53 mutations in human immunodeficiency virus-related head and neck squamous cell carcinoma.
    Gleber-Netto FO; Zhao M; Trivedi S; Wang J; Jasser S; McDowell C; Kadara H; Zhang J; Wang J; William WN; Lee JJ; Nguyen ML; Pai SI; Walline HM; Shin DM; Ferris RL; Carey TE; Myers JN; Pickering CR;
    Cancer; 2018 Jan; 124(1):84-94. PubMed ID: 29053175
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Response of head and neck squamous cell carcinoma cells carrying PIK3CA mutations to selected targeted therapies.
    Wirtz ED; Hoshino D; Maldonado AT; Tyson DR; Weaver AM
    JAMA Otolaryngol Head Neck Surg; 2015 Jun; 141(6):543-9. PubMed ID: 25855885
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The effect of LKB1 on the PI3K/Akt pathway activation in association with PTEN and PIK3CA in HNC.
    Ekizoglu S; Dogan S; Ulker D; Seven D; Gozen ED; Karaman E; Buyru N
    Clin Otolaryngol; 2015 Dec; 40(6):622-8. PubMed ID: 25850957
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Feasibility of Targeting PIK3CA Mutations in Head and Neck Squamous Cell Carcinoma.
    Theurer JA; Stecho W; Yoo J; Kwan K; Wehrli B; Harry V; Black M; Pinto N; Winquist E; Palma D; Richter S; Barrett JW; Danielle MacNeil S; Fung K; Howlett CJ; Nichols AC
    Pathol Oncol Res; 2016 Jan; 22(1):35-40. PubMed ID: 26271341
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeted sequencing reveals TP53 as a potential diagnostic biomarker in the post-treatment surveillance of head and neck cancer.
    van Ginkel JH; de Leng WW; de Bree R; van Es RJ; Willems SM
    Oncotarget; 2016 Sep; 7(38):61575-61586. PubMed ID: 27528217
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Deguelin Potentiates Apoptotic Activity of an EGFR Tyrosine Kinase Inhibitor (AG1478) in PIK3CA-Mutated Head and Neck Squamous Cell Carcinoma.
    Baba Y; Maeda T; Suzuki A; Takada S; Fujii M; Kato Y
    Int J Mol Sci; 2017 Jan; 18(2):. PubMed ID: 28134774
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Incorporation of Next-Generation Sequencing into Routine Clinical Care to Direct Treatment of Head and Neck Squamous Cell Carcinoma.
    Chau NG; Li YY; Jo VY; Rabinowits G; Lorch JH; Tishler RB; Margalit DN; Schoenfeld JD; Annino DJ; Goguen LA; Thomas T; Becker H; Haddad T; Krane JF; Lindeman NI; Shapiro GI; Haddad RI; Hammerman PS
    Clin Cancer Res; 2016 Jun; 22(12):2939-49. PubMed ID: 26763254
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Detection of
    Borkowska EM; Barańska M; Kowalczyk M; Pietruszewska W
    Biomolecules; 2021 May; 11(6):. PubMed ID: 34072735
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeted next-generation sequencing of locally advanced squamous cell carcinomas of the head and neck reveals druggable targets for improving adjuvant chemoradiation.
    Tinhofer I; Budach V; Saki M; Konschak R; Niehr F; Jöhrens K; Weichert W; Linge A; Lohaus F; Krause M; Neumann K; Endris V; Sak A; Stuschke M; Balermpas P; Rödel C; Avlar M; Grosu AL; Abdollahi A; Debus J; Belka C; Pigorsch S; Combs SE; Mönnich D; Zips D; Baumann M;
    Eur J Cancer; 2016 Apr; 57():78-86. PubMed ID: 26896955
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification of genomic mutations associated with clinical outcomes of induction chemotherapy in patients with head and neck squamous cell carcinoma.
    Ock CY; Son B; Keam B; Lee SY; Moon J; Kwak H; Kim S; Kim TM; Jeon YK; Kwon SK; Hah JH; Lee SH; Kwon TK; Kim DW; Wu HG; Sung MW; Heo DS
    J Cancer Res Clin Oncol; 2016 Apr; 142(4):873-83. PubMed ID: 26677030
    [TBL] [Abstract][Full Text] [Related]  

  • 14. PI3K/PTEN/AKT/mTOR polymorphisms: association with clinical outcome in patients with head and neck squamous cell carcinoma receiving cetuximab-docetaxel.
    Pfisterer K; Fusi A; Klinghammer K; Knödler M; Nonnenmacher A; Keilholz U
    Head Neck; 2015 Apr; 37(4):471-8. PubMed ID: 24421178
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PIK3CA mutations in head and neck squamous cell carcinoma.
    Qiu W; Schönleben F; Li X; Ho DJ; Close LG; Manolidis S; Bennett BP; Su GH
    Clin Cancer Res; 2006 Mar; 12(5):1441-6. PubMed ID: 16533766
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Frequent mutation of the PI3K pathway in head and neck cancer defines predictive biomarkers.
    Lui VW; Hedberg ML; Li H; Vangara BS; Pendleton K; Zeng Y; Lu Y; Zhang Q; Du Y; Gilbert BR; Freilino M; Sauerwein S; Peyser ND; Xiao D; Diergaarde B; Wang L; Chiosea S; Seethala R; Johnson JT; Kim S; Duvvuri U; Ferris RL; Romkes M; Nukui T; Kwok-Shing Ng P; Garraway LA; Hammerman PS; Mills GB; Grandis JR
    Cancer Discov; 2013 Jul; 3(7):761-9. PubMed ID: 23619167
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Search for mutations in signaling pathways in head and neck squamous cell carcinoma.
    De Carvalho TG; De Carvalho AC; Maia DC; Ogawa JK; Carvalho AL; Vettore AL
    Oncol Rep; 2013 Jul; 30(1):334-40. PubMed ID: 23670291
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Gene status of head and neck squamous cell carcinoma cell lines and cetuximab-mediated biological activities.
    Kondo N; Tsukuda M; Taguchi T; Nakazaki K; Sakakibara A; Takahashi H; Toth G; Nishimura G
    Cancer Sci; 2011 Sep; 102(9):1717-23. PubMed ID: 21631644
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Exploiting high-throughput cell line drug screening studies to identify candidate therapeutic agents in head and neck cancer.
    Nichols AC; Black M; Yoo J; Pinto N; Fernandes A; Haibe-Kains B; Boutros PC; Barrett JW
    BMC Pharmacol Toxicol; 2014 Nov; 15():66. PubMed ID: 25428177
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Analysis of PIK3CA and Akt/protein kinase B in head and neck squamous cell carcinoma.
    Fenic I; Steger K; Gruber C; Arens C; Woenckhaus J
    Oncol Rep; 2007 Jul; 18(1):253-9. PubMed ID: 17549376
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.